XML 22 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cover Page - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Feb. 28, 2025
Jun. 30, 2024
Document Information [Line Items]      
Entity Registrant Name NUVATION BIO INC.    
Document Type 10-K    
Current Fiscal Year End Date --12-31    
Amendment Flag false    
Entity Central Index Key 0001811063    
Entity Current Reporting Status Yes    
Entity Filer Category Non-accelerated Filer    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Address, Address Line One 1500 Broadway    
Entity Address, Address Line Two Suite 1401    
Entity Address, City or Town New York    
Entity Address, Postal Zip Code 10036    
City Area Code 332    
Local Phone Number 208-6102    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity File Number 001-39351    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 85-0862255    
Entity Interactive Data Current Yes    
Entity Address, State or Province NY    
Document Transition Report false    
Document Annual Report true    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Public Float     $ 522,742,050
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Name KPMG LLP    
Auditor Location New York, NY    
Auditor Firm ID 185    
Documents Incorporated by Reference [Text Block]

Certain portions of the registrant's definitive proxy statement relating to the Company's Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.

    
Auditor Opinion

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external reporting purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

    
Class A Common Stock [Member]      
Document Information [Line Items]      
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 Per Share    
Trading Symbol NUVB    
Security Exchange Name NYSE    
Entity Common Stock, Shares Outstanding   337,678,855  
Class B Common Stock      
Document Information [Line Items]      
Entity Common Stock, Shares Outstanding   1,000,000  
Redeemable Warrants [Member]      
Document Information [Line Items]      
Title of 12(b) Security Warrants to Purchase Class A Common Stock    
Trading Symbol NUVB.WS    
Security Exchange Name NYSE